Navigation Links
Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
Date:1/11/2008

MONTVALE, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories, Inc. in connection with its Namenda(R) (memantine hydrochloride) tablets, 5mg and 10mg.

Barr filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Namenda product with the U.S. Food & Drug Administration (FDA) on October 16, 2007, the first date the FDA could accept an ANDA with a paragraph IV certification for this product. Following receipt of the notice from the FDA that Barr's ANDA had been accepted for filing, Barr notified the New Drug Application (NDA) and patent holder.

On January 10, 2008, Forest Laboratories Holdings, Ltd., Forest Laboratories, Inc., Merz Pharma GmbH & Co. KgaA, and Merz Pharmaceuticals GmbH filed suit in the U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Namenda (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. The product had sales of approximately $824 million in the U.S., based on IMS sales data ending October 2007.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal su
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
6. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. Pressure BioSciences, Inc. Issued First Patent in Canada
9. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
10. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
11. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... flow abnormalities found in the brains of veterans with Gulf ... in some cases have gotten worse, according to a new ... "We confirmed that abnormal blood flow continued or worsened over ... the damage is ongoing and lasts long term," said principal ...
... Mo. Researchers at the University of Missouri have found ... may help future crops fight off dangerous diseases. ... to the mustard plant, fends off infectious agents," said Walter ... S. Bond Life Sciences Center and Interdisciplinary Plant Group. "We ...
... today the establishment of a collaboration with Ono ... and development of small molecule modulators of an ... terms of the agreement, Receptos will use its ... crystal structures of the discovery target and drive ...
Cached Biology Technology:Study finds chronic abnormal brain blood flow in Gulf War veterans 2MU researchers identify key plant immune response in fight against bacteria 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 3
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Angeles, Calif.: Stand Up To Cancer (SU2C) announced ... high-risk/high-reward cancer research conducted by 13 young scientists. Over ... of up to $750,000 as part of SU2C,s Innovative ... cancer research leaders. "We asked our best and ...
... Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist ... Uvalde, has been investigating ways to help vegetable plants ... the field. "This research can aid in the ... some vegetable crops by producing high-quality, more adaptive plants ...
... release is available in German . , ... of Ageing could help to understand the positive effect of ... (fruit flies and mice) have shown that dietary restriction increases ... fertility. So the female fruit fly reproduces less frequently with ...
Cached Biology News:Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How nutrition affects healthy aging 2
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
... strains are high-performance BL21 ... protein yield in T7 ... 1). Because the T7 ... more rapidly than E. ...
Biology Products: